Market Overview

Why Jefferies Upgraded Johnson & Johnson

Related JNJ
Biotech Winners And Losers From Congress' Latest Funding Bill
Checking In On The Healthcare Sector Ahead Of Q1 Earnings Season
Rituxan biosimilar captures 80% of British market (Seeking Alpha)

On CNBC's "Power Lunch", Jefferies analyst Jeffrey Holford spoke about his upgrade of Johnson & Johnson (NYSE: JNJ).

He upgraded the stock to Buy and he increased its price target to $157 from $145. Holford sees the acquisition of Actelion as important and he thinks it's going to have a faster impact because Johnson & Johnson isn't taking all of its R&D infrastructure. The biggest driver of his Buy rating are the products that are already in the company, especially the oncology division.

Holford added that Talcum powder lawsuits shouldn't have a major impact on the company, because the big studies show no connection to cancer. The company has a strong balance sheet and it can deal with significant liabilities. He also thinks Johnson & Johnson would be interested in buying Pfizer's (NYSE: PFE) consumer health business.

Latest Ratings for JNJ

Feb 2018CitigroupMaintainsNeutralNeutral
Feb 2018CitigroupMaintainsNeutralNeutral
Jan 2018Stifel NicolausMaintainsHoldHold

View More Analyst Ratings for JNJ
View the Latest Analyst Ratings

Posted-In: CNBC Jefferies Jeffrey HolfordAnalyst Color Upgrades Price Target Analyst Ratings Media


Related Articles (JNJ + PFE)

View Comments and Join the Discussion!